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Abstract
Major depression is the most prevalent psychiatric disorder which affects 20% of the
population in the united states, and the prevalence is twice as high in women than men (Porth,
2014). A literature review of the prevalence of major depression among ICU survivals revealed
that being female increased the likelihood for major depressive disorder five times compared
with men in the ICU (Asimakopoulou, 2014). There is also an increasing incidence in
adolescents and children, and also a higher prevalence with people with family history of mood
disorder. Major depression affects up to 37 percent of American adults and is more common
among women than among men. In adolescence, girls are twice as likely as boys to be diagnosed
with depression (Romanowski, 2004). There are many theories of the etiology of major
depressive disorder (MDD), including evolutional theory, genetic influence, dysregulation of
neurotransmitter model, psychosocial theories, and biological basis which includes abnormalities
in brain chemistry. Dopamine is a neuromediator in the brain, it is located in the substantia nigra
and ventral segmental area in the midbrain, derived from tyrosine. It is involved in motivation,
thoughts, emotions. “Dopamine is thought to play a role in anhedonia (lack of pleasure in usual
activities) which is often experienced by patients with depression” (Perese, 2012).
The patient in the case report presented with severe major depressive disorder, passive thoughts
of death, with a comorbid substance use disorder. Upon further evaluation, pharmacotherapy was
initiated to stabilize the patient and improve sleep. The Patient disposition after stabilization in
inpatient psychiatry includes safe housing, connecting with an outpatient mental health provider
which includes psychotherapy services. These actions appear to be in line with most
recommendations for mental health professionals in the literature reviewed.
Background
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Most adults with major depressive disorder (MDD) fail to achieve remission with index
pharmacological treatment. Moreover, at least half will not achieve and sustain remission
following multiple pharmacological approaches. The goal of treatment now is complete
remission of symptoms, then maintaining a level of improvement so that depression does not
relapse shortly after remission, nor does that patient have a recurrent episode in the future.
The case presentation takes a look at a patient suffering from recurrent depression with chronic
suicidal ideation, generalized anxiety with substance use disorder. The patient has seemed not to
benefit from past treatment plans/ options modality and currently endorse severe episode of
depression. Knowing the unlikelihood of achieving complete remission, and how it declines with
each successive treatment attempt, the purpose of the report is to compare and contrast the
efficacy of psychotherapy and pharmacotherapy in treating depression and anxiety disorders.
Case Report
Patient is a 55-year-old male with a past medical history significant for diabetes mellitus
II, seizures, past suicide attempts, asthma, obstructive sleep apnea, personality disorder,
traumatic brain injury (TBI), substance abuse who was admitted with altered mental status and
suicide attempt by overdose by an unknown substance in an attempt to take his life. The patient
psych history includes a number of inpatient psychiatric hospitalizations for depression, suicidal
ideation when drinking, most recently twice within the past 2 months. Pt appears to be currently
seeing an outpatient psych provider, and some engagement with psychotherapy per chart review.
Upon interview with the patient, he reports that he has been feeling depressed lately due to the
social stressors of losing his apartment, being homeless, and also stressors of living in
environments like the public shelters, having his money and food stolen, and substance use to the
point where he wants to commit suicide. Patient further reports that he currently is staying in a
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shelter and has been waiting for assistance with housing but it’s going slow and he is tired of
waiting. He reports frustration, sadness, helplessness, hopelessness, feeling worthless, poor sleep
with racing thoughts, poor appetite, anxiety, and passive thoughts of death. Patient denies
hallucinations, voices, mood swings, mania, and thoughts to hurt others. Prior to hospitalization,
the patient stated he was on Zoloft and Trazodone which he avoids when he drinks and endorses
using cocaine on occasions. The patient says he “drinks sometimes to kill my problems” and
wants to take something that prevents him from “feeling so down all the time”. On observation,
the mood appears depressed, attention/concentration is slow, insight/judgement is poor, thought
process and speech are slow, and the patient appears dysphoric. Pt is homeless, currently
unemployed, the support system includes a brother, currently on probation for a felony
conviction for domestic assault by strangulation, also has a history of armed robbery as a
teenager, served three years in prison. Pt has been a victim of trauma in the past, history of
stabbing to the abdomen, head injury due to assault, and a gunshot wound to the chest.
Patient has past psych medication trials which include but not limited to Depakote, Trazodone,
Keppra, Lyrica, Celexa, and Zoloft, no history of ECT, no history of MI/CD commitment.
Patient has been in CD treatment about 5 times, endorsed poor choices while in treatment, and
identifies alcohol use as the only dependency he believes she has trouble overcoming.
Working diagnoses at the moment are Alcohol use Disorder, Moderate, Cocaine Use Disorder,
Moderate, Major Depressive Disorder, Recurrent episode vs Substance/Medication-induced
Depressive Disorder, Rule out Post Traumatic Stress Disorder symptoms, Rule out personality
disorders and malingering behaviors. The plan is to hospitalize patient in inpatient psychiatry for
further stabilization, restart home meds that include Zoloft, Trazodone, Gabapentin, also consult
to addiction medicine for recommendations, possible chemical dependency treatment social
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work assistance with disposition, having financial counselors involved for financial assistance,
and reconnecting patient back with an outpatient provider and individual therapy. Thus, leading
to the comparing, contrasting the efficacy of pharmacotherapy, psychotherapy, or the
combination of both in the treatment of depression and anxiety.
Literature Review
According to (Grieken et al., 2015), by the year 2030, depression is estimated to be the
leading cause of burden of disease in high-income countries. The article describes a need for
improvement from traditional evidenced based on depression management due to recurrent
episodes. An approach to improvement is the addition of effective self-management strategies.
Although self-management in general medicine is mostly related to coping with a chronic
disease, it is interesting that in the case of depression, information on the Internet and in (selfhelp) books suggests that self-management could help in particular in the ‘recovery from’ instead
of ‘coping with’ the disease (Grieken et al., 2015). The patients in the study agreed that the focus
for recovery must be behavioral and cognitive strategies. Key findings in the article are the
different number of self-management strategies from patients’ perspective that contributes to
their recovery. Some of these strategies include having a proactive attitude towards depression
and treatment, daily life strategies and goals, being able to explain the disease to others,
remaining socially engaged, engaging in activities, structured attention to oneself, contact with
fellow sufferers. Self-management can be an alternative or supportive treatment introduced to
depressed patients.
The article by Muneoka, 2009 looks into the effectiveness of duloxetine, an SNRI in the
treatment of major depressive disorder and anxiety. Depression is associated with anxiety and
physiological and psychological pain. In a 4 day in clinical trials by Muneoka, 2009 on rats, 20
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mg/day of duloxetine induced a marked increase in Serotonin levels. A Longer-term (21-day)
treatment of rats with duloxetine increased the electrically stimulated release of 5-HT and NA in
the hippocampus and midbrain. The study also demonstrated an anxiolytic-like effect when
treating the animals with duloxetine, “it significantly increased the time animals spent in open
areas in the zero-maze suggesting an anxiolytic action of the drug” (Muneoka, 2009). Adverse
effects of duloxetine were also taking into consideration, with trials on healthy people,
ventricular repolarization when assessed by QT prolongation was not affected. Thus, showing
duloxetine to be safe when administered within therapeutic dose range. In a short-term
observation (7-9weeeks) of measuring its efficacy on MDD, duloxetine 60 mg/day was superior
to placebo in reducing the score on the 17-item Hamilton Rating Scale for Depression (HAM-D17) 2 weeks after administration began. “Reported remission rates were 43%–58% in the shortterm studies” (Muneoka, 2009). Longer-term studies showed that patients had a significantly
longer time to relapse while on duloxetine compared to placebo, and also shows a 70% – 75%
remission rate. “Three short-term (10 weeks) placebo-controlled studies indicated the superior
effects of duloxetine (60–120 mg/day) compared with placebo in reducing the Hamilton Anxiety
Rating Scale (HAM-A) score” Muneoka, 2009). In a longer-term study with patients with GAD,
it also shows a greater improvement of the quality of life when compared to the placebo.
Implications for practice shows its effectiveness in treating MDD, dysthymia, GAD, and painrelated diseases such as fibromyalgia.
In the study by Hassan et al., 2017, they compared how patients with a dual diagnosis of
opioid use disorder with mood and anxiety disorders can have variable prognosis due to
receiving opioid agonist therapies (OAT). Thus, they embark on examining the efficacy of
pharmacotherapy in the treatment of symptoms of depression or anxiety in patients on OAT.
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“Patients with OUD have a high incidence of affective symptoms, such as depression and
anxiety, also have poor outcomes, poor quality of life, severe substance abuse, and psychosocial
impairment” (Hassan et al., 2017). Their study also shows that opioid agonist therapy can
effectively treat OUD, but about a quarter of the patients did not experience improved mood after
the therapy. An early RCT compared cognitive behavioral therapy (CBT) to non-directive group
therapy in the treatment of 14 patients on methadone. Patients in the CBT group had a highly
significant reduction in symptoms of depression and anxiety than patients in the control group.
“In comparison to pharmacotherapy, treatment with psychotherapy consistently decreased
symptoms of depression in patients with dual diagnosis. These results demonstrate that the use of
psychotherapies is beneficial for patients in OAT in general. There were no significant
differences between various psychotherapies in term of their effectiveness in alleviating either
symptom of depression or anxiety” (Hassan et al., 2017). Their metanalysis of RCT’s also shows
that patients with persistent symptoms of depression responded better to TCA than SSRI
treatment. Hassan et al. (2017) conclude on psychotherapy being more effective than
pharmacotherapy in treating symptoms of depression and anxiety in patients on OAT due to
decreasing the stress of the individual’s negative environment, and also enhancing the
therapeutic alliance by providing empathy, support, or acceptance of distressing thoughts. “In
addition, targeting early maladaptive schemas might be beneficial to assist with symptoms of
depression and anxiety in patients with OUD” (Hassan et al., 2017).
A case report demonstrating the efficacy of psychotherapy in treating depression and
anxiety in polycystic ovarian syndrome (PCOS) shows a scarcity of available evidence-based
study in the use of psychotherapy in this population. Correa et al., (2015) suggested the PCOS
Workbook that uses the cognitive-behavioral framework in treating symptoms of anxiety,
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depression, and problematic eating in a 19-year-old female previously diagnosed with PCOS.
“Women with PCOS produce an elevated amount of androgens, causing hormone imbalances
that could produce infertility, insulin resistance, and obesity, and also vulnerable to developing
mental health problems due to hormone imbalances” (Correa et al., 2015). The use of CBT in
treating these symptoms helps create cognitive restructuring that can help improve psychological
functioning and also help in adopting lifestyle changes that may be necessary for managing the
disorder. The subject of the case reports “change in problematic symptoms, as well as body
weight, throughout the course of therapy. The participant experienced a consistent, significant
reduction in BDI-II scores and BAI scores during the course of treatment. Scores on both
measures dropped from the severe range at intake to the normal range at termination and
remained in the normal range 6 months after termination” (Correa et al., 2015). The participant
also stated that the cognitive restructuring was very helpful, and it contributed to her long-term
success. Though PCOS workbook shows an effectiveness in helping with depression and anxiety
symptoms, the authors felt a need for a more rigorous randomized clinical trials against active
controls, such as other empirically supported interventions are needed.
Meaney-Tavares & Hasking, 2013 conducted a study to analyze the efficacy of a pilot
program, aimed at treating college students with a borderline personality disorder (BPD) using
short-term, modified group dialectical behavior therapy at an Australian college counseling
service. Since remission in BPD takes about 1 -3 years of therapy before significant clinical
improvements, a preliminary pilot of a modified (DBT) group named “Coping and Regulating
Emotions” (CARE) was created with the hope the CARE program could result in a decrease in
self-reported anxiety, depression, and BPD criterion-related behaviors and an increase in
adaptive coping skills. It consisted of the 4 DBT modules; includes conceptual frameworks, such
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as the neurobiological underpinnings of emotion and behavior, and language and examples
relevant to college students. Seventeen enrolled college students aged between 18 and 28 (76.5%
female), with a diagnosis of BPD completed the program between November 2009 and
November 2010. Eight 2-hour group therapy sessions were held, and participants were assessed
for levels of depression, anxiety, BPD traits, and coping strategies, at commencement and
completion of the program. “Over the 8-week period, the mean scores indicated a decrease from
the lower end of a severe range of depressive symptoms (29–63) to the upper end of a mild range
of symptoms (14–19)” (Meaney-Tavares & Hasking, 2013”. With a reduction in symptoms
of depression and BPD traits, and an increase in adaptive coping skills, including problemsolving, and constructive self-talk, it shows the modified DBT can be effective in minimizing the
distress caused to this population through difficulties in obtaining an appropriate external
referral.
Primary care providers now are now expected to be able to assess and treat depression as
it is a leading cause of global disease burden and tends to be managed in primary care settings in
many places around the world. Arroll et al, 2016 looks into the effectiveness of antidepressants
in primary care, also examining the efficacy of different individual agents. They argued that most
current practice guidelines show studies done in secondary and tertiary settings, and in situations
where patients were mostly moderate- severely depressed, and a need for updated guidelines for
mild depression mostly encountered in primary care. Thus, they embarked on assessing the
effectiveness of all classes of antidepressants versus placebo in primary care patients. Results
suggested “antidepressants are effective when compared with placebo for depression in primary
care. There were four broad medication groups, including TCA, SSRI, SNRI, and NaSSA, and
all had evidence of efficacy in the current review of participants with mild to moderate severity
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in primary care” (Arroll et al., 2016). Implications for practice showed evidence in some
individual agents such as amitriptyline, mianserin, sertraline, escitalopram, venlafaxine due to
evidence, but does not necessarily means more effective than other agents that lacked research
evidence. The article did specify on the need to conduct more studies on agents that lacked
evidence in the treatment of depression in primary care.
In treating major depressive disorders, questions have always arisen on what the initial
treatment should be. Markowitz (2008) argues that clinicians often do not think carefully before
deciding and that psychotherapy may be overlooked too often as a first treatment option. Also,
treatment bias by clinicians tends to influence or determine which interventions they select for
their patients rather than by treatment guidelines or the empiric outcome research literature. “The
choice of initial treatment is hardly trivial; it consigns a patient to a particular mode of therapy
for a period of weeks or months” (Markowitz, 2008). If treatment choice is ineffective, the
patient may become increasingly hopeless in their condition and may drop out of other treatment
options that may alleviate their symptoms. In patients with mild depression, antidepressants may
not be needed, as “psychotherapy- CBT, interpersonal therapy, and dynamic psychotherapy- has
been found to be equivalent to the use of antidepressant medications” (Perese, 2012). The author
suggested the indication for psychotherapy in practice should be a patient preference, symptom
severity, nature of symptoms, prior treatment history, psychosocial context, and contraindication
to pharmacotherapy. Significant psychosocial stressors, intrapsychic conflict, interpersonal
difficulties, or a comorbid Axis II disorder complicates treatment, and thus psychotherapy may
be more beneficial. The author concludes combined treatment is the treatment of choice for
patients with chronic or severe depressive episodes, but also that psychotherapy is only as good
as their therapists. Thus, the choice of a good empirically supported psychotherapy and a good
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therapist can improve mild to moderate depressive symptoms, and “psychotherapy may keep on
working even after acute treatment has been terminated as a result of learned new skills”
(Markowitz, 2008).
Perese (2012), estimated that about two-thirds of patients with depressive disorder
experience some improvement following treatment with the first antidepressant that is used- that
is, they experience at least a 50% reduction of their symptoms; however, less than 50% of
patients achieve remission. SSRIs are usually the first line agent for the treatment of depression,
and it is also helpful in treating a number of anxiety disorders, eating disorders, premenstrual
dysphoric disorder. Preliminary evidence suggested that sertraline might be slightly superior in
terms of effectiveness. Cipriani et al., 2010, looks into the effectiveness of Sertraline versus other
anti-depressive agents for depression. In their study, they found evidence favoring sertraline over
some other antidepressants for the acute phase treatment of major depression, either in terms of
efficacy (fluoxetine) or acceptability/tolerability (amitriptyline, imipramine, paroxetine, and
mirtazapine). However, some differences favoring newer antidepressants in terms of efficacy
(mirtazapine) and acceptability (bupropion) were also found” (Cipriani et al., 2010). The author
also highlighted that participants experienced a higher rate of diarrhea while sertraline but was
also highly favored in a systematic review in terms of efficacy and tolerability. Sertraline appears
to be well tolerated, had proven efficacy and is a recommended first line of antidepressant for
clinicians.
The associated cost to society and health care systems of depressive disorders are well
documented. Qaseem, A., Barry, M. J., & Kansagara, D. (2016) in their article estimated the economic burden associated with depression was $83.1 billion in 2000 and is higher today. The
effectiveness of pharmacology and non-pharmacology are well documented in the literature,
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publications, and practice guidelines. The authors discussed practice guidelines based on
systematic review of RCTs for pharmacologic and non-pharmacologic treatment of adult patients
with major depressive disorder. In their review, monotherapy of second-generation
antidepressants when compared to CBT shows no difference in response in patients with MDD
after 8 to 52 weeks of treatment. Also, combined therapy of both showed no difference in
response or remission when compared to monotherapy in patients with MDD after 12 to 52
weeks of treatment. Qaseem, A., Barry, M. J., & Kansagara, D. (2016) summarized that most
patients do not achieve remission after initial treatment with SGAs, in which case switching
therapies or augmenting with additional interventions such as non-pharmacologic treatment may
be warranted. An implication for practice is the strong consideration of CBT as a reasonable
approach for an alternative treatment to SGAs where available due to adverse effects and or risk
of discontinuation.
Cuijpers et al., (2013) compared the efficacy of psychotherapy and antidepressant
medications in treating in all types of depressive, anxiety disorders, and whether all types of
psychotherapy and antidepressants are equally efficacious for each disorder. The authors argued
it remains unclear whether all types of psychotherapy and all types of antidepressant medications
have comparable effects. In one previous meta-analysis, “they found that treatment with selective
serotonin reuptake inhibitors (SSRIs) was somewhat more effective than treatment with
psychotherapy, whereas tricyclic antidepressants (TCAs) and psychotherapy were equally
effective” (Cuijpers et al., 2013). A re-analysis of those data, however, showed that there were
no significant differences between psychotherapy and SSRIs after adjusting for differential dropout from both treatments. Another meta-analysis confirmed that psychotherapy and SSRIs were
equally effective when only bona fide psychotherapies were included. In providing stronger
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evidence, Cuijpers et al., (2013) compared systematic search results of 67 randomized trials,
including 5,993 patients that met inclusion criteria, 40 studies focusing on depressive disorders
and 27 focusing on anxiety disorders. In conclusion, they found both psychotherapy and
pharmacotherapy to have comparable effects in anxiety and depressive disorders, except in OCD
and dysthymia. Evidence suggested that psychotherapy was significantly more efficacious in
OCD and that pharmacotherapy was significantly more efficacious in dysthymia.
Patients value and prioritize functioning and quality of life over symptoms management.
Meaning a depressed patient having a relative relief from their depressive symptoms from
pharmacotherapy and an adverse effect of sexual dysfunction might not adhere to that treatment
regimen due to loss of quality of life. Furthermore, improvement in functioning and quality of
life has been considered the ultimate outcome measure that indicates whether certain treatments
have succeeded. With the quality of life as a priority, Kamenov et al., (2016) metanalysis of
RCTs was to determine the absolute and relative effects of psychotherapy, pharmacotherapy and
their combination on functioning and quality of life in patients with depression. In conclusion,
Kamenov et al., (2016) provide comprehensive evidence that existing psychological and
pharmacological interventions are efficacious for improving functioning and quality of life in
depression. In comparing psychotherapy v. pharmacotherapy in functioning and quality of life,
there was no significant difference. There is no robust evidence that one of the interventions is
superior, although psychotherapy appears slightly superior to medication when both are
compared to controlled conditions.
Implications
While pharmacotherapy and psychotherapy are both equally effective in the treatment of
depressive and anxiety disorders, major difference seems to be in determining when it is
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appropriate to initiate either or both therapy. The literature reviewed showed no evidence in the
superiority of a therapy choice over the other over an extended period of time. The combination
of both combined therapy against either treatment alone appears to be significantly better for
both quality outcomes. The literature also shows psychotherapy to be adequate in treating mild to
moderate depression, some anxiety disorders, in mild to a moderately depressed patient that
prefers non-pharmacologic interventions, or in situations where pharmacological side effects are
intolerable. The modest effects suggest that future research should focus on tailoring therapies to
better cover the needs of individuals, thus implication for clinicians to tailor treatment based on
evidence, patient’s acuity, and patient preference.
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